Enzalutamide
- Generic Name
- Enzalutamide
- Brand Names
- Xtandi, Enzalutamide Viatris
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16F4N4O2S
- CAS Number
- 915087-33-1
- Unique Ingredient Identifier
- 93T0T9GKNU
- Background
Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012. Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieve...
- Indication
Enzalutamide is indicated for the treatment of castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer (mCRPC). It is also used in combination with talazoparib for the treatment of adult patients with HRR gene-mutated mCRPC.
- Associated Conditions
- Castration Resistant Prostate Cancer, Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Associated Therapies
- -
A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2023-04-19
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 200
- Registration Number
- NCT05818683
- Locations
- 🇺🇸
Washington University School Of Medicine, Saint Louis, Missouri, United States
🇺🇸Sidney Kimmel Cancer Center - Jefferson Health, Philadelphia, Pennsylvania, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2024-11-14
- Target Recruit Count
- 26
- Registration Number
- NCT05751941
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-02-24
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 30
- Registration Number
- NCT05743621
- Locations
- 🇺🇸
Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York, New York, United States
Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-02-17
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Emory University
- Target Recruit Count
- 30
- Registration Number
- NCT05733351
- Locations
- 🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-02-16
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 25
- Registration Number
- NCT05730712
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 90
- Registration Number
- NCT05726292
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
- Conditions
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT05701007
- Locations
- 🇫🇮
Pfizer, Helsinki, Finland
A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- MacroGenics
- Target Recruit Count
- 382
- Registration Number
- NCT05551117
- Locations
- 🇺🇸
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇧🇪Centre Hospitalier Universitaire (CHU) - Universite Catholique de Louvain (UCL) - Namur - Site Godinne (Cliniques Universitaires UCL de Mont-Godinne), Godinne, Namur, Belgium
🇺🇸Fred Hutchinson Cancer Center, Seattle, Washington, United States
A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide
- Conditions
- Interventions
- First Posted Date
- 2022-09-02
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Bayer
- Target Recruit Count
- 65
- Registration Number
- NCT05526248
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Central Ohio Urology Group, Columbus, Ohio, United States
Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Conditions
- Interventions
- First Posted Date
- 2022-08-29
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 5506
- Registration Number
- NCT05520138
- Locations
- 🇺🇸
Pfizer Inc, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.